Last reviewed · How we verify
YTS109 cell
At a glance
| Generic name | YTS109 cell |
|---|---|
| Sponsor | China Immunotech (Beijing) Biotechnology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia (PHASE1)
- An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases (PHASE1)
- A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia (PHASE1)
- A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases (PHASE1)
- Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases (PHASE1)
- A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases (PHASE1)
- YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases (PHASE1)
- A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YTS109 cell CI brief — competitive landscape report
- YTS109 cell updates RSS · CI watch RSS
- China Immunotech (Beijing) Biotechnology Co., Ltd. portfolio CI